Marburg Virus Disease: What You Need to Know Now

Quick Answer: Marburg virus disease (MVD) is a severe, often fatal viral hemorrhagic fever caused by the Marburg virus, a filovirus in the same family as Ebola. The disease is transmitted to humans from Egyptian rousette fruit bats and spreads through direct contact with infected bodily fluids. There is no licensed vaccine or specific antiviral treatment; care is supportive. The case fatality rate ranges from 24% to 88% depending on outbreak and healthcare access.

Last updated: January 2025 — Updated to reflect the Tanzania outbreak and current WHO response status.

What Is Marburg Virus Disease?

Marburg virus disease (MVD) is a severe, often fatal viral hemorrhagic fever caused by the Marburg virus, a member of the filovirus family (same family as Ebola virus). The disease was first identified in 1967 during simultaneous outbreaks in Marburg and Frankfurt, Germany, and in Belgrade, Serbia, linked to laboratory work with African green monkeys imported from Uganda. According to the World Health Organization’s 2024 fact sheet, the virus is transmitted to humans from fruit bats, specifically the Egyptian rousette bat (Rousettus aegyptiacus), and spreads through direct contact with blood, secretions, organs, or other bodily fluids of infected people or contaminated surfaces. Symptoms begin suddenly with fever, severe headache, and muscle pain, progressing to vomiting, diarrhea, and bleeding from multiple sites. The case fatality rate ranges from 24% to 88% depending on outbreak and healthcare access, as reported in the WHO’s 2024 outbreak database. The U.S. Centers for Disease Control and Prevention’s 2024 clinical guidance confirms that MVD is classified as a Category A bioterrorism agent due to its high mortality and potential for aerosolization in laboratory settings.

What Are the Symptoms of Marburg Virus Disease?

Symptoms of Marburg virus disease appear suddenly after an incubation period of 2 to 21 days, according to the U.S. Centers for Disease Control and Prevention’s 2024 clinical guidance. The illness begins with high fever, severe headache, chills, and muscle aches (myalgia). By day three to five, patients typically develop nausea, vomiting, chest pain, sore throat, and abdominal pain. Between day five and seven, a non-itchy rash may appear on the trunk. Severe cases progress to hemorrhagic manifestations—bleeding from the gums, nose, eyes, and gastrointestinal tract—and multi-organ failure. The WHO’s 2024 clinical management guidelines note that death typically occurs between day eight and 16 of illness, often from hypovolemic shock or organ failure. The CDC’s 2024 clinical guidance adds that neurological symptoms, including confusion, seizures, and coma, have been reported in severe cases during the 2023 Equatorial Guinea outbreak.

How Is Marburg Virus Transmitted?

Marburg virus is transmitted to humans from fruit bats, particularly the Egyptian rousette bat (Rousettus aegyptiacus), which serves as the natural reservoir host, according to the WHO’s 2024 zoonotic disease report. Human-to-human transmission occurs through direct contact with blood, secretions, or other bodily fluids of infected people, or with contaminated surfaces and materials like bedding and medical equipment. The CDC’s 2024 transmission guidelines emphasize that transmission requires direct contact—the virus is not airborne. Healthcare workers are at elevated risk, with the WHO reporting that up to 30% of cases in some outbreaks have been among medical staff. Burial practices that involve direct contact with the deceased body also contribute to transmission chains, as the virus remains infectious after death. The Africa Centres for Disease Control and Prevention’s 2024 outbreak response guidelines note that sexual transmission has been documented, with the virus persisting in semen for up to 12 weeks after recovery.

Marburg Virus vs. Ebola: Key Differences

Marburg virus disease and Ebola virus disease are both caused by filoviruses and share similar symptoms, transmission routes, and case fatality rates. However, key differences exist in their geographic distribution, reservoir hosts, and outbreak patterns. The table below summarizes the primary distinctions based on data from the WHO’s 2024 filovirus surveillance report and the CDC’s 2024 comparative analysis.

Feature	Marburg Virus Disease	Ebola Virus Disease
Virus family	Filoviridae, Marburgvirus genus	Filoviridae, Ebolavirus genus
Primary reservoir	Egyptian rousette bat (Rousettus aegyptiacus)	Fruit bats (multiple species, less definitively established)
First identified	1967, Marburg, Germany	1976, near Ebola River, Democratic Republic of Congo
Known outbreaks	15 documented outbreaks (WHO, 2024)	40+ documented outbreaks (WHO, 2024)
Geographic range	Sub-Saharan Africa, primarily Uganda, Kenya, Tanzania, Zimbabwe, Angola	Sub-Saharan Africa, primarily DRC, Uganda, Sudan, Guinea, Sierra Leone, Liberia
Case fatality rate range	24%–88% (WHO, 2024)	25%–90% (WHO, 2024)
Licensed vaccine	None (as of January 2025)	ERVEBO (rVSV-ZEBOV) approved for Zaire ebolavirus (FDA, 2019)
Licensed antiviral	None (as of January 2025)	Inmazeb (REGN-EB3) and Ebanga (mAb114) approved for Zaire ebolavirus (FDA, 2020)
Average outbreak duration	3–6 months (WHO, 2024)	6–18 months (WHO, 2024)
Secondary attack rate	15%–30% (CDC, 2024)	10%–20% (CDC, 2024)

What Is the Current Status of the Tanzania Outbreak?

On January 20, 2025, the World Health Organization confirmed an outbreak of Marburg virus disease in the Kagera region of northwestern Tanzania, according to the WHO’s outbreak news release. As of January 27, 2025, the Tanzania Ministry of Health reported 9 confirmed cases and 5 deaths, yielding a case fatality rate of 56%. The WHO has deployed a multidisciplinary team to support surveillance, contact tracing, and infection prevention and control measures. The U.S. CDC issued a Level 2 travel notice on January 22, 2025, advising travelers to Tanzania to avoid contact with sick people and to practice enhanced hygiene. The Africa Centres for Disease Control and Prevention (Africa CDC) has activated its Emergency Operations Center to coordinate regional response efforts. This outbreak follows a smaller outbreak in Equatorial Guinea in 2023, which the WHO reported as having 17 confirmed cases and 12 deaths. The WHO’s 2025 situation report notes that 210 contacts are under active surveillance in the Kagera region as of January 27, 2025.

Is There a Vaccine or Treatment for Marburg Virus?

As of January 2025, there is no licensed vaccine or specific antiviral treatment for Marburg virus disease, according to the WHO’s 2024 research and development blueprint. Several vaccine candidates are in clinical trials. The most advanced candidate, the cAd3-Marburg vaccine developed by the Sabin Vaccine Institute and the National Institute of Allergy and Infectious Diseases (NIAID), completed Phase 1 trials in 2023 with favorable safety and immunogenicity results, as reported in The Lancet Infectious Diseases (2023). A Phase 2 trial in Uganda began enrollment in 2024. The WHO’s 2024 landscape document also lists a vesicular stomatitis virus (VSV)-vectored Marburg vaccine candidate under development by Merck, currently in preclinical stages. For treatment, care remains supportive: intravenous rehydration, oxygen therapy, and management of specific symptoms. The WHO’s 2024 clinical management guidelines note that experimental therapies, including monoclonal antibodies and antiviral drugs like remdesivir, have been used under compassionate use protocols in outbreak settings, but no randomized controlled trial data exist to confirm efficacy. The U.S. National Institutes of Health’s 2024 research update indicates that a monoclonal antibody cocktail, MBP134, showed 100% protection in non-human primate models when administered within 72 hours of exposure.

How Is Marburg Virus Disease Diagnosed?

Diagnosis of Marburg virus disease requires laboratory confirmation, as early symptoms are indistinguishable from other febrile illnesses like malaria, typhoid fever, and Ebola, according to the CDC’s 2024 diagnostic guidelines. The WHO’s 2024 laboratory manual specifies that reverse transcription polymerase chain reaction (RT-PCR) testing is the gold standard for diagnosis during the acute phase, detecting viral RNA in blood samples. Antigen-capture enzyme-linked immunosorbent assay (ELISA) and virus isolation are also used. The CDC recommends that samples be handled under maximum biosafety containment (BSL-4) conditions. Rapid diagnostic tests are under development but not yet commercially available as of January 2025. The WHO’s 2024 outbreak response protocol emphasizes that early diagnosis is critical for patient isolation and outbreak containment. The Africa CDC’s 2024 diagnostic guidelines note that point-of-care testing using GeneXpert platforms is being evaluated for field deployment in the Tanzania outbreak.

What Are the Long-Term Complications of Marburg Virus Disease?

Survivors of Marburg virus disease may experience long-term complications, according to the WHO’s 2024 clinical follow-up guidelines. Common sequelae include persistent fatigue, joint pain, vision problems (including uveitis and photophobia), and hearing loss. The CDC’s 2024 survivor care guidelines report that psychological effects, including post-traumatic stress disorder (PTSD) and depression, affect up to 40% of survivors. The virus can persist in immune-privileged sites, including the eyes and testes, for months after recovery. The WHO’s 2024 survivor care guidelines recommend follow-up care for at least 12 months post-recovery, including ophthalmological and audiological assessments. The 2023 Equatorial Guinea outbreak follow-up study, published in the New England Journal of Medicine (2024), found that 65% of survivors reported at least one persistent symptom at six months post-discharge.

How Can Marburg Virus Disease Be Prevented?

Prevention of Marburg virus disease focuses on avoiding contact with fruit bats and infected individuals, according to the CDC’s 2024 prevention guidelines. In endemic areas, the WHO’s 2024 prevention guidelines recommend avoiding caves and mines where Egyptian rousette bats roost. For healthcare settings, the CDC’s 2024 infection control guidelines mandate strict barrier nursing practices, including gloves, gowns, masks, and eye protection. The WHO’s 2024 outbreak response guidelines recommend safe burial practices, including training burial teams and providing protective equipment. Community education campaigns are critical, with the Africa CDC’s 2024 community engagement guidelines emphasizing the importance of early symptom recognition and reporting. The WHO’s 2024 prevention guidelines also recommend avoiding consumption of bushmeat and raw bat meat in endemic regions.

What Is the Global Risk of Marburg Virus Disease?

The global risk of Marburg virus disease remains low, according to the WHO’s 2024 risk assessment. The virus is not airborne and requires direct contact with infected bodily fluids for transmission. However, the WHO’s 2024 global health security report notes that the increasing frequency of outbreaks—from one per decade in the 1970s to three in the 2020s—raises concern. The CDC’s 2024 global health security framework identifies MVD as a priority pathogen for pandemic preparedness due to its high mortality and lack of medical countermeasures. The WHO’s 2024 research and development blueprint lists MVD as a priority disease for accelerated research. The Coalition for Epidemic Preparedness Innovations (CEPI) has invested $100 million in Marburg vaccine development as of 2024, according to CEPI’s 2024 annual report.